Incyte(US:INCY) Businesswire·2025-11-17 06:00Core Viewpoint - Incyte has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding Minjuvi® (tafasitamab) for the treatment of relapsed or refractory follicular lymphoma (FL) [1] Company Summary - Incyte is advancing its product Minjuvi® (tafasitamab) for patients with relapsed or refractory follicular lymphoma, indicating a significant step in its oncology portfolio [1] - The positive CHMP opinion is a crucial milestone that may lead to expanded market access for Minjuvi® in Europe [1] Industry Summary - The approval process for oncology treatments like Minjuvi® reflects the ongoing demand for effective therapies in the oncology sector, particularly for challenging conditions such as follicular lymphoma [1] - The positive opinion from CHMP may influence competitive dynamics within the oncology market, as companies seek to address unmet medical needs in hematological malignancies [1]